Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA03 - Biomarkers for Immunotherapy: Are All Relevant?
- 10:45 - 11:45
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
MA03.01 - EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer
10:45 - 10:50 | Presenter: Silvia Garcia-Roman
- Abstract
Loading... -
+
MA03.02 - TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
10:50 - 10:55 | Presenter: Edward B Garon
- Abstract
Loading... -
+
MA03.03 - NBTXR3 Activated by SBRT Combined with Nivolumab or Pembrolizumab in Patients With Advanced Cancers: Phase I Trial
10:55 - 11:00 | Presenter: Colette Shen
- Abstract
Loading... -
+
MA03.04 - Discussant
11:00 - 11:15 | Presenter: Giannis Mountzios
- Abstract
No abstract available for this presentation
-
+
MA03.05 - DNA Damage Response (DDR) Gene Mutations and Correlation With Immunotherapy Response in NSCLC Patients
11:15 - 11:20 | Presenter: Jiaqing Liu
- Abstract
Loading... -
+
MA03.06 - ctDNA Mass-Adjusted bTMB as a Predictive Biomarker in NSCLC Patients Receiving PD-(L)1 Inhibitors
11:20 - 11:25 | Presenter: Wei Nie
- Abstract
Loading... -
+
MA03.07 - Interferon-Gamma Mediated Immune Evasion: A Potential Mechanism of Resistance to Immunotherapy in Non-Small Cell Lung Cancer
11:25 - 11:30 | Presenter: Fasheng Li
- Abstract
Loading... -
+
MA03.08 - Discussant
11:30 - 11:45 | Presenter: Solange Peters
- Abstract
No abstract available for this presentation
-
+
MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma
- 10:45 - 11:45
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
-
+
MA04.01 - Multimodality Treatment and Outcome in Stage III Thymic Epithelial Tumors (TETs): A Retrospective Analysis From the French RYTHMIC Network
10:45 - 10:50 | Presenter: Jose Carlos Benítez
- Abstract
Loading... -
+
MA04.02 - Characteristics of Genomic Alterations in Chinese Patients with Thymic Epithelial Tumors
10:50 - 10:55 | Presenter: Xinglong Fan
- Abstract
Loading... -
+
MA04.03 - A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17-21)
10:55 - 11:00 | Presenter: Hyun Ae Jung
- Abstract
Loading... -
+
MA04.04 - Discussant
11:00 - 11:15 | Presenter: Paul Baas
- Abstract
No abstract available for this presentation
-
+
MA04.05 - Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma
11:15 - 11:20 | Presenter: Ahmed Alnajar
- Abstract
Loading... -
+
MA04.06 - MicroRNAs Contribute to the Chemotherapy Response of Malignant Pleural Mesothelioma
11:20 - 11:25 | Presenter: Michaela B Kirschner
- Abstract
Loading... -
+
MA04.07 - Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
11:25 - 11:30 | Presenter: Susana Cedres
- Abstract
Loading... -
+
MA04.08 - Discussant
11:30 - 11:45 | Presenter: Francoise Galateau-Salle
- Abstract
No abstract available for this presentation
-
+
OA05 - Palliative Care Service Models
- 10:45 - 11:45
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Palliative and Supportive Care
- Moderators:Maria Ftanou
-
+
OA05.01 - Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With an Advanced Thoracic Malignancy
10:45 - 10:55 | Presenter: Kelly C. Gast
- Abstract
Loading... -
+
OA05.02 - Acceptability of Automatic Referrals to Supportive and Palliative Care, by Patients Living with Advanced Lung Cancer: A Co-Design Process
10:55 - 11:05 | Presenter: Desiree Hao
- Abstract
Loading... -
+
OA05.03 - Onco-Pall Clinic: An Embedded Care Model for Thoracic Malignancy
11:05 - 11:15 | Presenter: Julia Lynn Agne
- Abstract
Loading... -
+
OA05.04 - Discussant
11:15 - 11:25 | Presenter: Brian Le
- Abstract
No abstract available for this presentation
-
+
OA05.05 - Live Discussion with Speakers
11:25 - 11:45
- Abstract
No abstract available for this presentation
-
+
IS01 - Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC
- 12:00 - 13:00
- 9/08/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
-
+
IS01.01 - Welcome and Introduction
12:00 - 12:05 | Presenter: Pasi A. Janne
- Abstract
No abstract available for this presentation
-
+
IS01.02 - Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC
12:05 - 12:20 | Presenter: Suresh Ramalingam
- Abstract
No abstract available for this presentation
-
+
IS01.03 - Targeting Checkpoint Inhibitor Resistance in NSCLC
12:20 - 12:35 | Presenter: Solange Peters
- Abstract
No abstract available for this presentation
-
+
IS01.04 - Advances In NSCLC: Targeted Therapies, Including Targeting KRAS-Driven NSCLC
12:35 - 12:50 | Presenter: Pasi A. Janne
- Abstract
No abstract available for this presentation
-
+
IS01.05 - Live Q&A
12:50 - 13:00
- Abstract
No abstract available for this presentation
-
+
IS02 - Satellite CME Symposium by Med Learning Group: A New Era of Treatment Opportunities for Small-Cell Lung Cancer in the Second Line: An Innovative 3D View
- 12:00 - 13:00
- 9/08/2021
- Location: Program Auditorium
- CME Accredited by Other Provider
- Type: Satellite CME Symposia
- Track: N.A.
-
+
IS02.01 - Response to Primary Therapy and Tumorigenesis of Small Cell Lung Cancer: Subsequent Lines of Therapy and Pathophysiology Primer
12:00 - 12:15
- Abstract
No abstract available for this presentation
-
+
IS02.02 - Efficacy and Safety Review: Second-Line Regimens for Extensive Stage SCLC
12:15 - 12:30
- Abstract
No abstract available for this presentation
-
+
IS02.03 - Applying National Cancer Center Network (NCCN) Guidelines to Practice
12:30 - 12:45
- Abstract
No abstract available for this presentation
-
+
IS02.04 - Conclusions
12:45 - 12:50
- Abstract
No abstract available for this presentation
-
+
IS02.05 - Live Q&A
12:50 - 13:00
- Abstract
No abstract available for this presentation
-
+
IS03 - Satellite CME Symposium by RMEI Medical Education: Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects
- 12:00 - 13:00
- 9/08/2021
- Location: Program Auditorium
- CME Accredited by Other Provider
- Type: Satellite CME Symposia
- Track: N.A.
-
+
IS03.01 - Welcome and Introductions
12:00 - 12:05 | Presenter: Tony Mok
- Abstract
No abstract available for this presentation
-
+
IS03.02 - EGFR Insertion Mutations in NSCLC: Why and How Do We Test?
12:05 - 12:20 | Presenter: Shirish M. Gadgeel
- Abstract
No abstract available for this presentation
-
+
IS03.03 - New and Emerging Therapies with EXON20 INS Mutations
12:20 - 12:40 | Presenter: Tony Mok
- Abstract
No abstract available for this presentation
-
+
IS03.04 - Managing Toxicity with Anti-EGFR Exon 20 Agents
12:40 - 12:50 | Presenter: Antonio Passaro
- Abstract
No abstract available for this presentation
-
+
IS03.05 - Audience Q&A and Closing Remarks
12:50 - 13:00
- Abstract
No abstract available for this presentation
-
+
FP01 - Early Stage/Localized Disease/Ablative Therapies
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
FP01.01 - The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC
00:00 - 00:00 | Presenter: John Varlotto
- Abstract
Loading... -
+
FP01.02 - A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)
00:00 - 00:00 | Presenter: Ricardo Mingarini Terra
- Abstract
Loading... -
+
FP01.03 - Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
00:00 - 00:00 | Presenter: Sabine Schmid
- Abstract
Loading... -
+
FP01.04 - Prospective Observational Study of Activities of Daily Livings in Elderly Patients After Lung Cancer Surgery (JCOG1710A)
00:00 - 00:00 | Presenter: Hidefumi Takei
- Abstract
Loading...
-
+
FP02 - Health Services Research/Health Economics
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Health Services Research/Health Economics
-
+
FP02.01 - Utilization and Refusal of Adjuvant Chemotherapy for Non-Small Cell Lung Cancer: A National Cancer Database Study
00:00 - 00:00 | Presenter: Ranjan Pathak
- Abstract
Loading... -
+
FP02.02 - The Impact of Sex on Non-Small Cell Lung Cancer Survival in Canada
00:00 - 00:00 | Presenter: Chelsea Ann Ford-Sahibzada
- Abstract
Loading... -
+
FP02.03 - Factors Associated With Delayed Lung Cancer Diagnosis
00:00 - 00:00 | Presenter: Andrew Ciupek
- Abstract
Loading... -
+
FP02.04 - Immunotherapy in Lung Cancer: Analysis of Patients’ Awareness and Perceptions
00:00 - 00:00 | Presenter: Christie Lagogianni
- Abstract
Loading...
-
+
FP03 - Immuno-Biology and Novel Immunotherapeutics (Phase I and Translational)
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
FP03.02 - A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients with Metastatic Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jyoti Malhotra
- Abstract
Loading... -
+
FP03.03 - ECOG PS of 0-1 and Very High PD-L1 Expression ≥90% Are Associated With Clinical Benefit From First-Line Chemo-Immunotherapy in Advanced NSCLC
00:00 - 00:00 | Presenter: Biagio Ricciuti
- Abstract
Loading... -
+
FP03.04 - Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Conversion and Proliferation
00:00 - 00:00 | Presenter: Esther Redin
- Abstract
Loading...
-
+
FP04 - Immunotherapy (Phase II/III Trials)
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
-
+
FP04.01 - Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907
00:00 - 00:00 | Presenter: Natasha Leighl
- Abstract
Loading... -
+
FP04.02 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
00:00 - 00:00 | Presenter: Jie Wang
- Abstract
Loading... -
+
FP04.03 - Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
00:00 - 23:59 | Presenter: Igor Bondarenko
- Abstract
Loading... -
+
FP04.04 - A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017
00:00 - 00:00 | Presenter: Muhammad Furqan
- Abstract
Loading...